DESIGNER BABIES: CAN PARENTS REALLY CHOOSE THEIR FUTURE CHILD?

Inside a modern IVF laboratory, several embryos may exist outside the body during one treatment cycle. They are tiny clusters of cells, not miniature babies, but they already carry genetic information from two future parents.

Doctors can sometimes test a few cells from an embryo before deciding which embryo to transfer. That can help families avoid certain serious inherited diseases.

It also creates one of the most difficult questions in modern medicine: if science can tell parents something about embryos before pregnancy begins, what should they be allowed to do with that information?

The question usually begins with disease prevention. It quickly moves toward more controversial territory: sex selection, complex disease risk, height, intelligence, appearance and even gene editing.

When does preventing disease become designing a child?

The first answer is clarity. IVF is not the same as embryo screening. Screening is not the same as embryo selection. Selection is not the same as gene editing. Confusing those steps is how science-fiction headlines turn into public misunderstanding.

For wider PRESDA context on genetics, medicine and AI-assisted healthcare, read the history of medicine and PRESDA's AI coverage.

What Are Designer Babies?

Designer babies is a popular phrase, not a precise medical category.

It can refer to embryo testing, embryo selection, sex selection, polygenic screening, genetic enhancement or heritable gene editing. Those are very different things.

The phrase is powerful because it suggests parents might order traits the way someone customizes a product: eye color, height, intelligence, personality, athletic ability or disease resistance.

That is not what current reproductive medicine can reliably do.

Modern IVF and genetic testing can provide meaningful choices in specific situations, especially for families at risk of serious single-gene disorders. But parents cannot currently design a child's intelligence, personality, face, height or athletic ability to order.

What Is IVF?

IVF means in vitro fertilization: fertilization outside the body.

A typical IVF cycle may involve ovarian stimulation, egg retrieval, fertilization with sperm in a laboratory, embryo development for several days, embryo transfer into the uterus and cryopreservation of additional embryos where appropriate.

Those steps are medically complex, emotionally intense and physically demanding. But IVF itself does not genetically modify a child.

IVF creates the possibility of testing embryos because embryos are present in a laboratory before transfer. That is why IVF became the doorway to preimplantation genetic testing.

Can Parents Choose Embryos With IVF?

Sometimes, but the word choose needs context.

If several embryos are available, doctors and patients may decide which embryo to transfer based on embryo development, appearance under the microscope, chromosomal testing, known disease risk, clinic policy, law and patient preferences.

That does not mean parents can choose from endless possibilities. An IVF cycle may produce few embryos, one embryo or no embryos suitable for transfer. Some patients never have a large set of options.

Selection is constrained by biology before it is constrained by ethics.

What Is PGT?

PGT stands for preimplantation genetic testing.

PGT-M tests for specific monogenic disorders: conditions caused mainly by pathogenic variants in one gene, such as Huntington disease, cystic fibrosis, sickle cell disease or Tay-Sachs disease.

PGT-SR tests embryos when a parent carries a structural chromosome rearrangement that can increase the risk of miscarriage or serious chromosomal imbalance.

PGT-A screens chromosome number, looking for aneuploidy: embryos with missing or extra chromosomes. Its use, benefits and limitations vary by patient group and remain debated in some contexts.

None of these tests guarantees a healthy baby. They provide information about particular genetic or chromosomal questions.

Can IVF Prevent Genetic Disease?

In some families, PGT-M can dramatically reduce the chance of having a child affected by a known serious inherited condition.

If both parents carry variants associated with an autosomal recessive disorder, some embryos may inherit two disease-causing copies while others may not. If one parent carries a dominant condition such as Huntington disease, some embryos may inherit the pathogenic variant and others may not.

Testing can help identify embryos that are not expected to develop that specific condition.

This is one of the strongest medical arguments for embryo testing. It is not about ordering a perfect child. It is about helping families avoid a severe disease they already know is present in their genetic risk.

Can Parents Choose Their Baby's Sex?

In IVF contexts, embryo testing can sometimes reveal chromosomal sex.

Whether parents may use that information for non-medical sex selection depends heavily on country, law, professional rules and clinic policy.

In the United States, non-medical sex selection is not banned by one national fertility law in the same way it is in some countries, though clinic policies and professional ethics matter. In the United Kingdom, the HFEA allows sex selection only for medical reasons, not for family balancing or preference. Many European jurisdictions restrict or prohibit non-medical sex selection.

There is no global rule. A legal option in one country may be prohibited in another.

Medical sex selection can be ethically different when used to avoid serious sex-linked disease.

Can Parents Choose Eye Color?

Eye color sounds simple, but genetics is rarely a clean menu.

Some genetic variants are associated with eye color, and prediction may be easier for broad categories than for many other traits. But ancestry, multiple genes and incomplete prediction matter.

A clinic advertising trait selection does not automatically prove reliable, ethical or medically supported capability.

Prediction is not the same as ordering. Even if an embryo has a higher probability of one eye color, that does not make the future child a custom-designed product.

Can Parents Choose Height?

Height is a polygenic trait, meaning it is influenced by many genetic variants. It is also shaped by environment, nutrition, health, development and chance.

Polygenic scores estimate genetic tendency by adding information from many DNA variants. But embryos from the same parents are genetically similar compared with unrelated people, so the range available for selection within one IVF cycle is limited.

If parents have only a few embryos, the realistic difference in predicted adult height may be small. If they have many embryos, selection power increases, but still does not become certainty.

A genome is not a height dial.

Can Parents Choose Intelligence?

Intelligence and cognitive performance are much more complicated than popular marketing suggests.

They involve many genetic variants, environment, education, nutrition, development, family context, health, measurement problems and social opportunity. The same genetic associations may not predict equally well across populations.

Selecting an embryo with a higher predicted score does not mean creating a genius. It does not guarantee personality, motivation, creativity, kindness, memory, emotional health or achievement.

Current science cannot reliably offer parents a high-IQ baby to order.

Any claim that it can should be treated with skepticism.

What Is Polygenic Embryo Screening?

Polygenic embryo screening, often marketed as PGT-P, estimates relative genetic risk for complex traits or diseases using polygenic risk scores.

Possible applications discussed by companies and researchers include risk estimates for heart disease, type 2 diabetes, some cancers and other multifactorial conditions.

The key word is estimate.

A polygenic score is not a diagnosis. It may describe relative risk compared with a reference population, not a guaranteed outcome for a future child. Absolute risk can remain low. Environmental factors can dominate. Results can be less accurate for people whose ancestry is underrepresented in genomic datasets.

ASRM's 2026 committee opinion says PGT-P should not be offered as a routine clinical service until more research and counseling standards support its use.

That does not mean the idea is impossible forever. It means routine use is not currently supported as settled medicine.

One Trait Can Affect Another

Genes often have more than one effect. This is called pleiotropy.

A genetic profile associated with lower risk for one condition may also be associated with higher risk for another outcome, or with effects we do not yet understand.

That is why embryo selection becomes ethically and scientifically difficult when it moves beyond clear single-gene disease.

A genome is not a list of independent sliders.

Selecting for one predicted outcome can shift other probabilities in ways parents may never have intended.

Why Having More Embryos Changes The Equation

Selection power depends on the number of embryos available.

Parents normally cannot choose from thousands of embryos. Many IVF cycles produce only a limited number of embryos suitable for testing and transfer. Age, fertility diagnosis, egg number, sperm quality, lab outcomes and chance all matter.

If future technologies such as in-vitro gametogenesis ever allowed many more embryos to be created safely and ethically, selection could become more powerful. But reproductive use of lab-made human eggs or sperm is not established routine medicine today.

The number of embryos is not a footnote. It is central to what selection can realistically do.

Selection Is Not Editing

Embryo selection chooses among embryos that already exist.

Gene editing attempts to alter DNA.

A simple analogy helps: selection chooses a card from a hand. Editing attempts to rewrite the card.

That difference matters. Most current reproductive genetics involves testing and selection, not rewriting embryonic DNA.

Headlines that blend PGT and CRISPR create a false impression that routine IVF clinics are already manufacturing genetically edited children. They are not.

Can Scientists Edit Human Embryos?

Scientists can edit cells and embryos in research settings under strict rules in some jurisdictions, but that is different from approved clinical reproduction.

Laboratory capability does not equal legal approval. Legal approval does not equal routine medical practice. Research does not equal a safe fertility service.

CRISPR is a family of tools that can target DNA sequences. Newer techniques such as base editing and prime editing aim for more precise changes in some contexts.

But human embryo editing for reproduction remains ethically and scientifically controversial, and heritable editing is restricted or prohibited in many places.

CRISPR And Human Embryos

CRISPR is often described as genetic scissors, but the metaphor is incomplete. It is a molecular system that can be directed to particular DNA sequences, where it may cut or alter genetic material depending on the editing method.

Somatic gene editing affects cells in a treated person and is not intended to be inherited by future generations.

Germline or embryo editing could affect the future child and potentially descendants.

That is why heritable editing raises much greater safety and ethical concerns. It changes not only one patient's body, but possibly a biological lineage.

What Happened With The CRISPR Babies?

In 2018, Chinese scientist He Jiankui announced the birth of children whose embryos had been edited using CRISPR, targeting the CCR5 gene.

The announcement produced international condemnation. Scientists and ethicists criticized the work for safety, consent, medical necessity, transparency and governance failures.

The case did not prove that designer babies had arrived. It proved that the world was not ready for reckless heritable editing.

He Jiankui was later sentenced in China for illegal medical practice. The children should not be sensationalized; they are people whose privacy matters.

The scandal transformed global discussion around human germline editing because it showed that scientific possibility can outrun ethical governance.

Why Heritable Editing Is Different

If an adult receives a gene therapy, the intervention primarily concerns that patient.

Editing an embryo could affect a future child who cannot consent. If the change is heritable, it could also affect descendants.

Errors could propagate through a lineage. Mosaicism could mean not all cells carry the same edit. Off-target or unintended changes could have consequences that are difficult to predict at the embryo stage.

This is why many scientific bodies draw a bright line between treating existing patients and editing embryos for reproduction.

From Disease To Enhancement

Reproductive genetics exists on a spectrum.

At one end is preventing a lethal childhood disorder. Then comes reducing risk of adult disease. Then selecting sex. Then selecting predicted height. Then cognitive-associated scores. Then editing traits.

Where does medicine end and enhancement begin?

There is no universally agreed answer. Some people emphasize reproductive autonomy. Others worry that genetic choice could turn children into projects optimized against social expectations.

The question is not only what can be done. It is what should count as a medical reason.

What Counts As A Disease?

Some genetic conditions involve severe suffering, early death or profound medical burden.

Other traits involve disability communities whose members reject the idea that their lives should have been prevented.

This makes embryo selection ethically complex. A technology intended to reduce suffering can also send a social message about which lives are valued.

Disability-rights perspectives ask society to distinguish between preventing pain and implying that disabled people should not exist.

That distinction deserves respect.

The Return Of Eugenics?

Eugenics refers to movements that tried to improve human populations through reproductive control, often involving coercion, racism, class prejudice and state violence.

The 19th and 20th centuries saw forced sterilization, racial ideology, immigration restriction, institutional abuse and Nazi atrocities linked to eugenic thinking.

Modern IVF is not the same as Nazi eugenics.

But history warns us what can happen when societies assign different genetic traits different human value, especially when power, prejudice and reproduction meet.

The ethical lesson is not that all embryo testing is evil. It is that genetic choice requires humility, oversight and memory.

Who Decides What A Better Child Is?

Healthier? Taller? More intelligent? Less likely to become depressed? More athletic? A particular sex?

The definition of better is not only biological. It contains cultural judgments, family hopes, social pressure, ableism, sexism, class expectations and market incentives.

A parent may think they are choosing opportunity. A company may see a product. A society may start to treat certain traits as obligations.

The science cannot answer what a human life is worth.

Would Designer Babies Increase Inequality?

Advanced reproductive selection would likely be expensive, at least at first.

IVF already costs substantial money in many countries. Genetic testing adds cost. Travel, storage, medication, repeated cycles and specialist care can widen the gap between those with access and those without.

If genetic selection ever produced meaningful advantages, wealthy families could access them first.

That does not mean a science-fiction genetic class system is inevitable. But inequality is a serious concern because reproductive technology enters a world already unequal.

Would Parents Feel Pressure To Select?

A technology can be optional in law and pressured in culture.

If embryo screening becomes common, parents who decline it could be judged as irresponsible. Insurers, clinics, relatives or social expectations might nudge families toward testing.

Parents already face intense pressure to do everything possible for a future child.

The danger is that choice becomes obligation: if you could have selected, why didn't you?

What Happens To Embryos That Are Not Selected?

Outcomes depend on law, clinic policy and patient consent.

Embryos may remain cryopreserved, be considered for future transfer, be donated to another patient where permitted, be donated for research where permitted, or be disposed of according to legal and ethical procedures.

This subject should be handled with care.

Embryos are not medically the same as born babies. They are also not meaningless objects to many people. Neutral language matters because patients bring different moral, religious and emotional beliefs to IVF.

How Accurate Is Embryo Testing?

PGT results are useful but not absolute guarantees.

Testing often samples a few trophectoderm cells from the part of the embryo that contributes to the placenta. The result may not perfectly represent every cell. Mosaicism, laboratory limits, false positives, false negatives and interpretation uncertainty can matter.

Professional guidance often recommends genetic counseling and, where appropriate, prenatal confirmation after pregnancy.

PGT can reduce certain risks. It cannot promise a perfectly healthy child.

Why Genetic Predictions Can Fail Across Populations

Many genomic datasets historically overrepresent people of European ancestry.

Polygenic scores built from those datasets may perform less well for people with different ancestry backgrounds. That creates both scientific and equity problems.

A risk score that works better for one population than another can widen disparities if used clinically without careful validation.

This is one reason professional organizations are cautious about routine PGT-P.

Can AI Help Choose Embryos?

AI is being studied and used in some fertility contexts, especially for embryo image assessment, morphology scoring and implantation prediction.

But AI does not identify the best future child.

An algorithm may estimate which embryo appears more likely to implant based on images or clinic data. That is different from predicting a person's intelligence, character, happiness or life.

AI-assisted embryo assessment needs validation, transparency and accountability. It should not become a black box that turns human reproduction into a ranking dashboard.

The Business Of Fertility

Fertility medicine is also a business.

Clinics and genetic-screening companies may have incentives to market hope. Some claims are supported by peer-reviewed evidence and professional guidance. Others may move faster than consensus.

Patients should distinguish peer-reviewed evidence, regulatory permission, professional guidance, clinic practice and advertising language.

A service being sold does not prove it is clinically valuable.

This is especially important for polygenic embryo screening and trait prediction, where the emotional pressure on parents can be enormous.

Designer Babies: Myth Vs Reality

MYTH: Parents can currently design a child like a video-game character.

REALITY: No.

MYTH: IVF changes a baby's DNA.

REALITY: Standard IVF does not genetically edit embryos.

MYTH: PGT can guarantee a perfectly healthy baby.

REALITY: It cannot.

MYTH: Parents can reliably choose intelligence.

REALITY: Current prediction and selection are far too limited to promise a genius child.

MYTH: Embryo selection and CRISPR are the same.

REALITY: One selects among embryos; the other attempts to alter DNA.

MYTH: All countries allow sex selection.

REALITY: Laws and professional rules differ substantially.

MYTH: Scientists can safely edit human embryos for reproduction today.

REALITY: Research capability and clinically accepted heritable editing are very different things.

What Can Parents Actually Choose Today?

OPTION | POSSIBLE TODAY? | RELIABILITY | LEGAL/ETHICAL NOTES

Specific monogenic disease | Established in some clinical contexts | Strong when the familial variant is known | Requires counseling and lab validation

Chromosome information | Common in some IVF contexts | Useful but not perfect | PGT-A benefits vary by patient group

Embryo sex | Technically possible when chromosomal sex is known | High for chromosomal sex | Non-medical use is jurisdiction-dependent

Complex disease risk | Emerging and controversial | Probabilistic and limited | ASRM says routine PGT-P is not ready

Height | Poorly predictive for practical selection | Limited by polygenic complexity and embryo number | Enhancement concern

Eye color | Broad prediction may be possible in some cases | Not a reliable custom order | Marketing should be treated skeptically

Intelligence | Not clinically established | Far too limited for promises | Major ethical and scientific concerns

Personality | Not clinically established | Not reliably selectable | Human development is not a DNA menu

Athletic ability | Not clinically established | Not reliably selectable | Training, environment and chance matter

Gene-edited traits | Not accepted routine reproduction | Experimental and unsafe for clinical use | Heritable editing is restricted or prohibited in many places

What Could Change In The Next 10 To 20 Years?

Several things could change: better polygenic prediction, larger and more diverse genomic datasets, AI-assisted embryo assessment, improved gene-editing research, in-vitro gametogenesis research and new regulation.

Those are scenarios, not promises.

Better prediction does not automatically create ethical permission. More data does not eliminate social risk. New editing tools do not automatically make heritable editing safe.

The future may arrive gradually, through clinical menus expanding one option at a time.

Should Parents Be Allowed To Choose?

Arguments for expanded reproductive choice emphasize preventing severe disease, reducing suffering and respecting reproductive autonomy.

Arguments against expanded selection emphasize unknown risks, inequality, eugenic pressure, disability discrimination, effects on future generations and commodification of children.

Both sides can contain serious moral concerns.

The hardest cases are not the extremes. Most people support helping parents avoid devastating disease. Most people recoil from ordering a child like a luxury product.

The conflict is in the middle.

Can We Stop The Technology If Society Decides It Went Too Far?

Governance is difficult because reproductive medicine crosses borders.

Countries have different laws. Clinics compete internationally. Patients can travel. Procedures prohibited in one jurisdiction may be advertised in another.

This is sometimes called fertility tourism.

Global governance is possible only if regulators, professional societies, clinics, scientists and patients cooperate. Even then, enforcement will be uneven.

The Child Who Never Chose The Design

Parents already influence children profoundly: where they live, what they eat, which schools they attend, which languages they hear, which doctors they see and what values surround them.

Genetic selection differs because it can make decisions before the child exists, based on probabilities the child never consented to carry.

Does parental freedom include choosing biological probabilities for another person?

That question does not have a simple answer. But it should stay at the center of the debate.

Can Parents Really Choose Their Future Child?

Partly, and far less than the phrase designer baby suggests.

Modern IVF and genetic testing can provide meaningful choices in specific medical situations. In some jurisdictions they can reveal or influence selection based on sex. Emerging technologies may estimate some complex genetic risks.

But parents cannot reliably order a genius, a champion athlete, a specific personality, a precise face or a perfectly healthy child.

Human biology remains vastly more complicated.

The future of reproduction may not arrive with scientists building babies from scratch. It may arrive much more quietly, as a screen displaying several embryos and asking two parents to choose.

The science will tell us more and more about what those choices might mean.

It cannot tell us what we should value in a human being.